The m6A reader IGF2BP2 promotes pancreatic cancer progression through the m6A-SLC1A5-mTORC1 axis
Our findings suggest that IGF2BP2 promotes pancreatic cancer by activating the m6A-SLC1A5 -mTORC1 axis. Targeting the m6A machinery, particularly IGF2BP2, offers a novel therapeutic avenue for pancreatic cancer treatment. By disrupting the regulation of glutamine metabolism, we provide new insights into how m6A-based therapies could enhance the efficacy of current treatments and offer hope for improving patient outcomes in this difficult-to-treat cancer.
Authors
- Xiao Yuan (ORCID: https://orcid.org/0009-0004-9805-349X)
- Deqiang Wang (ORCID: https://orcid.org/0000-0002-3151-6769)
- Xi Pu (ORCID: https://orcid.org/0009-0008-2100-0524)
- Weiguo Long
- Yuting Wu (ORCID: https://orcid.org/0000-0002-6308-4331)
- Min Xu (ORCID: https://orcid.org/0009-0003-5839-0259)
- Xiwen Sun (ORCID: https://orcid.org/0000-0002-4881-4711)
- Xu Wang (ORCID: https://orcid.org/0000-0002-2092-4054)
Institutions
- Jiangsu University (CN)
- Affiliated Hospital of Jiangsu University (CN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1186/s12935-025-03736-8
- Citations
- 3
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province